3 reasons to buy the FTSE 100’s AstraZeneca stock now

Here’s why I’d be keen to get a solid-looking business such as AstraZeneca into my long-term diversified portfolio right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Scientist filling a needle

Image source: Getty Images.

FTSE 100 biopharmaceutical company AstraZeneca (LSE: AZN) is still around 19% down from its highs of last year. And with the share price near 7,564p the valuation looks modest considering the growth potential on offer.

The forward-looking earnings multiple for 2022 is around 16. And at least three reasons for buying the stock spring to my mind.

3 reasons to buy AstraZeneca stock

Firstly, the business is delivering strong growth in earnings. Over recent years, the research and development pipeline has been spitting out decent commercial pharmaceutical products. And there could be many more to come.

City analysts expect earnings to knock the ball out of the park in 2021 and increase by around 170% year-on-year. Then in 2022, they’ve pencilled in an earnings increase knocking on the door of 30%. Beyond that, we’ll have to wait and see. But AstraZeneca has rediscovered its growth mojo. And the company could be heading for a bright future.

A second reason for buying the stock is AstraZeneca’s modest level of debt on the balance sheet. What you see is what you get with the valuation and it’s not obscured by buckets full of borrowings. FTSE 100 peer GlaxoSmithKline, on the other hand, has a much bigger debt-load to account for when valuing the stock.

A third reason for buying AstraZeneca stock is the consistent record of shareholder dividend payments. One of the delights of the pharmaceutical sector is it tends to have less cyclicality than some other industries.

So, whether the economy is booming or busting, AstraZeneca tends to trade steadily, generating revenue, earnings and cash flow. And such constant finances can lead to a reliable stream of dividends for shareholders, as we’ve been seeing.

A solid-looking business

Right now, the forward-looking dividend yield is close to 2.8 for 2022. I admit that’s not a huge yield. But anticipated earnings should cover the payment more than twice. And it’s also backed by the strong cash flow the business enjoys. If earnings maintain their growth trajectory in the coming years, I think there’s a good chance we’ll see some decent annual rises in the dividend ahead.

I reckon the pandemic has underlined how vital the pharmaceutical sector is to society. So I’d be keen to get a solid-looking business such as AstraZeneca into my long-term diversified portfolio.

However, things may not work out as I hope for the business. Just a few years ago, for example, AstraZeneca was posting annual declines in earnings and battling a loss of revenue and profits because of patents running out. The so-called patent cliff faced by big pharmaceutical companies was well reported at the time. If the business stops posting earnings growth again, the valuation may start to look toppy and we could see share price declines leading to a losing investment in the stock.

But all shares come with risks. And in this case, I’d embrace the dangers and balance them against the firm’s growth potential. My plan would be to hold the stock for the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young brown woman delighted with what she sees on her screen
Investing Articles

The case for buying this dividend monster just got stronger!

This dividend monster just posted impressive earnings figures that sent its share price skyrocketing. So is now the time to…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

This one Ben Graham investment principle could make you richer

Legendary investor Warren Buffett applies a key principle he learnt from Ben Graham. Our writer explains why he thinks it…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

Is the Tullow Oil (TLW) share price poised to take off?

The Tullow Oil (TLW) share price has been more volatile than some of its bigger peers this year. But is…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Should I buy Royal Mail shares while they’re under 300p?

Royal Mail's share price has come down a long way in 2022 and is currently under 300p. Edward Sheldon looks…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

I’d forget buy-to-let and buy these REITs for passive income!

I think REITs are a great way to generate healthy streams of passive income. Here's why I think they're a…

Read more »

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

How I’d invest £5,000 in FTSE 100 shares to aim for a million

The FTSE 100 is home to many potential gems. Our writer considers if he can reach millionaire status by uncovering…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

How I’m aiming to become a Stocks and Shares ISA millionaire!

The Stocks and Shares ISA is an excellent vehicle for investments. In fact, many investors have become ISA millionaires. Here's…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

The Scottish Mortgage share price is on the up! Here’s why I’d buy

After a poor first half of the year, the Scottish Mortgage share price is beginning to rise. Here, this Fool…

Read more »